CN112689644B - 抗l1cam抗体及其用途 - Google Patents

抗l1cam抗体及其用途 Download PDF

Info

Publication number
CN112689644B
CN112689644B CN201980045545.5A CN201980045545A CN112689644B CN 112689644 B CN112689644 B CN 112689644B CN 201980045545 A CN201980045545 A CN 201980045545A CN 112689644 B CN112689644 B CN 112689644B
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
antibodies
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980045545.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN112689644A (zh
Inventor
洪孝正
蔡贺苏
洪吉苏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aibitai Biology Co ltd
Original Assignee
Aibitai Biology Co ltd
National Jiangyuan University University Industry University Cooperation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aibitai Biology Co ltd, National Jiangyuan University University Industry University Cooperation filed Critical Aibitai Biology Co ltd
Priority to CN202410882978.9A priority Critical patent/CN118754985A/zh
Priority to CN202510003352.0A priority patent/CN119930818A/zh
Priority claimed from PCT/IB2019/055472 external-priority patent/WO2020003210A1/en
Publication of CN112689644A publication Critical patent/CN112689644A/zh
Application granted granted Critical
Publication of CN112689644B publication Critical patent/CN112689644B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
CN201980045545.5A 2018-06-29 2019-06-27 抗l1cam抗体及其用途 Active CN112689644B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202410882978.9A CN118754985A (zh) 2018-06-29 2019-06-27 抗l1cam抗体及其用途
CN202510003352.0A CN119930818A (zh) 2018-06-29 2019-06-27 抗l1cam抗体及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR1020180075955A KR20200002451A (ko) 2018-06-29 2018-06-29 인간 l1cam 단백질에 특이적으로 결합하는 항체 및 이의 용도
KR10-2018-0075955 2018-06-29
US201962865871P 2019-06-24 2019-06-24
US62/865,871 2019-06-24
PCT/IB2019/055472 WO2020003210A1 (en) 2018-06-29 2019-06-27 Anti-l1cam antibodies and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202410882978.9A Division CN118754985A (zh) 2018-06-29 2019-06-27 抗l1cam抗体及其用途
CN202510003352.0A Division CN119930818A (zh) 2018-06-29 2019-06-27 抗l1cam抗体及其用途

Publications (2)

Publication Number Publication Date
CN112689644A CN112689644A (zh) 2021-04-20
CN112689644B true CN112689644B (zh) 2025-01-28

Family

ID=69154626

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980045545.5A Active CN112689644B (zh) 2018-06-29 2019-06-27 抗l1cam抗体及其用途

Country Status (6)

Country Link
JP (1) JP7527007B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200002451A (cg-RX-API-DMAC7.html)
CN (1) CN112689644B (cg-RX-API-DMAC7.html)
AU (1) AU2019293530B2 (cg-RX-API-DMAC7.html)
CA (1) CA3104252A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012680TA (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023078224A1 (zh) * 2021-11-03 2023-05-11 同润生物医药(上海)有限公司 新型抗l1cam抗体
CN115078738A (zh) * 2022-06-30 2022-09-20 复旦大学 一种l1cam蛋白n979位点特异性核心岩藻糖基化的抑制剂的应用
TW202417057A (zh) * 2022-10-26 2024-05-01 大陸商同潤生物醫藥(上海)有限公司 人源化的l1cam抗體藥物偶聯物
WO2024100200A1 (en) * 2022-11-09 2024-05-16 Cis Pharma Ag Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
CN118725118B (zh) * 2024-09-02 2024-11-22 北京凯祥弘康生物科技有限公司 抗人l1cam蛋白的抗体4d3
CN118725119B (zh) * 2024-09-02 2024-11-19 北京凯祥弘康生物科技有限公司 一种抗l1cam蛋白的抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104936984A (zh) * 2012-11-16 2015-09-23 江原大学校产学协力团 特异性结合人和小鼠l1cam的抗体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114550A1 (en) 2006-04-03 2007-10-11 Korea Research Institute Of Bioscience And Biotechnology A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same
KR101501736B1 (ko) * 2008-12-05 2015-03-12 한국생명공학연구원 인간 및 마우스에서 발현하는 l1cam에 특이적으로 결합하는 재조합 단일클론항체 및 그 이용
KR102058381B1 (ko) * 2012-08-24 2019-12-24 강원대학교산학협력단 인간 l1cam에 대한 인간화 항체 및 그의 제조 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104936984A (zh) * 2012-11-16 2015-09-23 江原大学校产学协力团 特异性结合人和小鼠l1cam的抗体及其用途

Also Published As

Publication number Publication date
KR102929858B1 (ko) 2026-02-26
KR20200002451A (ko) 2020-01-08
CN112689644A (zh) 2021-04-20
JP2021529776A (ja) 2021-11-04
CA3104252A1 (en) 2020-01-02
AU2019293530A1 (en) 2021-01-21
KR20210042091A (ko) 2021-04-16
AU2019293530B2 (en) 2025-10-09
SG11202012680TA (en) 2021-01-28
JP7527007B2 (ja) 2024-08-02

Similar Documents

Publication Publication Date Title
JP7527007B2 (ja) 抗l1cam抗体及びその使用
JP7530913B2 (ja) Cd73遮断抗体
TWI758928B (zh) 抗cd73抗體及其用途
AU2016335750B2 (en) IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
JP7740730B2 (ja) 抗l1cam抗体及びその使用
JP7012384B2 (ja) 癌治療のための抗fam19a5抗体の用途
JP2023120306A (ja) 配列類似性を持つ抗ファミリー19、メンバーa5抗体及びその用途
KR20140069172A (ko) 항­cd 134(ox40) 및 이의 용도
CN112119091B (zh) 抗序列相似家族19成员a5的抗体及其使用方法
CA3008819A1 (en) Antibodies specifically binding hla-dr and their uses
US20240376224A1 (en) Antibodies against cleaved cdcp1 and uses thereof
JP7728595B2 (ja) 二重特異性抗体及びその用途
CA3128104A1 (en) Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
JP2022084832A (ja) ヒト化抗ベイシジン抗体およびその使用
CN117964756A (zh) 抗序列相似家族19成员a5的抗体及其使用方法
CN119161478A (zh) α5β1整合素结合剂及其用途
KR102335799B1 (ko) 엔도텔린 수용체 a 활성 조절 항체
JP2022505144A (ja) Her2 s310f特異的な抗原結合分子
US12227566B2 (en) Endothelin receptor type a activity regulating antibody
KR20240099289A (ko) 항-cldn18.2 항체 및 그의 용도
HK40125826A (en) Anti-l1cam antibodies and uses thereof
EA053315B1 (ru) Антитела к l1cam и их применение
EA048894B1 (ru) Антитела к l1cam и их применение
WO2025038492A1 (en) Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210812

Address after: Seoul, South Kerean

Applicant after: Aibitai biology Co.,Ltd.

Address before: Gangwon-do

Applicant before: National Jiangyuan University University industry university cooperation

GR01 Patent grant
GR01 Patent grant